How many insider trades does FilingIQ track for CERS?

FilingIQ tracks 691 Form 4 insider transactions for CERS (CERUS CORP), covering filings from Aug 14, 2014 onwards. 29 of those were filed in the last 90 days.

Are CERS insiders net buyers or net sellers?

Across the full Form 4 history for CERS, 32 transactions (5%) were open-market purchases and 262 (38%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does CERS insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is CERS in?

CERUS CORP (CERS) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $465.50M.

CERS insider trading

NasdaqGM Healthcare

CERUS CORP — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

691

Last 90 days

Buys / sells

5% / 38%

Market cap

$465.50M

About CERUS CORP

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma and cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Company website: www.cerus.com

CERS insider activity at a glance

FilingIQ has scored 691 insider transactions for CERS since Aug 14, 2014. The most recent filing in our index is dated May 1, 2026.

Across the full history, 32 open-market purchases and 262 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on CERS insider trades is 59.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live CERS trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for CERS?: FilingIQ tracks 691 Form 4 insider transactions for CERS (CERUS CORP), covering filings from Aug 14, 2014 onwards. 29 of those were filed in the last 90 days.
Are CERS insiders net buyers or net sellers?: Across the full Form 4 history for CERS, 32 transactions (5%) were open-market purchases and 262 (38%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does CERS insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is CERS in?: CERUS CORP (CERS) is classified in the Healthcare sector, specifically Medical Devices, with a current market capitalisation of $465.50M.

Methodology & sources

Every CERS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.